UCB gets access to rights for an antibody program from WILEX for non-oncology indications

Brussels, Belgium / Munich, Germany, [10 July 2013] – UCB and WILEX AG (ISIN DE0006614720 / WL6 / FSE) announced today that UCB got access to an antibody program from the WILEX preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while WILEX keeps the rights to develop for oncology indications.

WILEX will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments and royalties.

UCB and WILEX will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to WILEX the relevant data to assist WILEX in oncology.

Ismail Kola, Executive Vice President and Chairman of New Medicine at UCB, said: "The pre-clinical work originated by UCB and continued by WILEX researchers to identify the immunology potential of one of the programs is of great interest to us. Leveraging UCB's scientific expertise in immunology, we will now take the program forward and explore it further in immunology indications where there are severe unmet needs".

Professor Olaf G. Wilhelm, Chairman of the Executive Management Board of WILEX AG, commented, "An identified lead antibody and generated data attracted UCB to purchase the rights to indications outside oncology at such an early stage which is not only a validation of our capabilities but also proof of our excellent partnership with UCB."

For further information UCB

Antje Witte, Investor Relations, UCB
T +32 2 559 9414, antje.witte@ucb.com

France Nivelle, Global Communications, UCB
T +32 2 559 9178, france.nivelle@ucb.com

Alexandra Deschner, Investor Relations, UCB
T +32 2 559 9683, alexandra.deschner@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com

For further information Wilex

Katja Arnold (CIRO) – PR Manager, Wilex AG Corporate Communications & IR

T +49 (0)89-41 31 38-126, investors@wilex.com

Notes to the editor

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

About Wilex

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer. In the field of therapeutics, WILEX develops antibodies and small molecules. (RENCAREX®: Phase III, MESUPRON®: Phase II, WX-554: Phase Ib/II and WX-037: preclinical). In the field of diagnostics, REDECTANE® is an antibody-based imaging agent that is currently in a Phase III programme. The Company also has a portfolio of biomarker assays that are marketed via its US subsidiary WILEX Inc. under the brand Oncogene Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and a highly promising antibody drug conjugate (ADC) technology platform. The business model of WILEX comprises research and product development as well as the commercialisation of its activities. WILEX's customers and partners include leading international pharmaceutical companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6.

UCB Forward-Looking Statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.